The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

Single-cell gene sequencing has changed the way scientists understand life at the smallest level. It lets researchers study ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

Bioluminescent luciferase enzymes have historically been too dim to use as probes in living tissue. But recent advances have ...

Avidity Biosciences (RNA) announced the completion of enrollment in the biomarker cohort in the Phase 1/2 Fortitude clinical trial of ...